Studies inhibiting FAK, reducing pTyr397, within invasive breast cancer and Ductal Carcinoma in Situ (DCIS) demonstrate decreased CSC activity and therapy resistance, which was associated with a reduction Wnt signalling12,14. This evidence concerns the gene PTK2 and ductal breast carcinoma in situ.